BEIJING, Aug.4 (Xinhua) -- The Chinese Ministry of Health issued an urgent circular ordering disuse of a problematic antibiotic glucose injection used to treat bacteria infections, which have caused serious symptoms among the patients.

The ministry demanded that all batches of clindamycin phosphate glucose injections produced in the past two moths by Huayuan Biopharmaceutical Co. Ltd. of Anhui Province, a branch of the medical giant Shanghai Huayuan Co.Ltd., be suspended from use immediately.

An increasing number of patients from provinces and regions including Qinghai, Guangxi, Zhejiang, Heilongjiang and Shandong have complained about symptoms ranging from chest distress, pain in the kidney of the body, bellyache, diarrhea, nausea, vomit, to anaphylactic shock after having been injected with the clindamycin phosphate glucose injections produced by the Anhui company.

But the ministry did not say if there had been any death caused by the problematic drug.

Fake of bad drugs have killed dozens of people in China in recent years and raised questions about drug safety.

The country has recently fined Qiqihar No.2 Pharmaceutical Co.Ltd. and revoked its licence after its drug meant to treat gastric disorders killed 11 people and turned out to be bogus.

While ordering that an inventory be made into the stockpile of the injections and all unused injections be sealed properly, the ministry circular also asked medical and health organizations not to purchase the injections made by the above-mentioned company.

In the meantime, the circular also told medical organizations to arrange medical workers to closely monitor patients who have had the injections and go all out to rescue those patients who have shown serious clinical symptoms.

Clindamycin phosphate glucose injections are mainly used to treat bacteria infections caused by gram-positive bacterium and gram-positive anaerobic bacterium. Side effects are mainly restricted to the gastrointestinal tract and anaphylactic reaction,sometimes coupled with abnormalities with the liver and kidney body parts.

Enditem

Injection medicine banned after patients reported in serious condition

BEIJING, Aug. 4 (Xinhua) -- China's Ministry of Health has banned a kind of injection medicine usually used to treat tonsillitis and bronchitis as patients in several provinces and autonomous regions were reported in serious conditions after taking the medicine.

The antibacterial medicine was manufactured by the Anhui Huayuan Biological Pharmaceutical Co. Ltd. affiliated to the Shanghai World best Co. Ltd., and its chemical name is clindamycin phosphate and glucose injection.

Patients in Qinghai, Zhejiang, Heilongjiang and Shandong provinces and Guangxi Zhuang Autonomous Region appeared syndromes such as decompensation, naupathia, diarrhea and loss of consciousness after dosing the medicine.

The Ministry of Health has demanded medical institutions at various levels to immediately stop using and purchasing the medicine made by the company since June.

The patients are now under observation in local hospitals and their conditions are being recorded and reported. The medicine has been taken sample for test and those already been sold are urgently recalled by local medical authorities. Enditem